Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
REVA Medical, Inc. (RVA.AX)
|
Add to portfolio |
|
|
|
| Price: |
$0.85
| | Metrics |
| OS: |
41.5
|
M
| |
|
|
| Market cap: |
$35.1
|
M
| |
-2257
|
% ROIC
|
|
Net debt:
|
$59.1
|
M
| |
|
|
|
EV:
|
$94.3
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($20.7)
|
M
| |
|
|
|
EBIT
|
($21.4)
|
M
| |
|
|
| EPS |
$0.22
| |
3.8
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13.4 | 0.0 |
| Revenue growth | | | | | | -100.0% | | -100.0% |
| Cost of goods sold | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 26.8 | 0.0 |
| Gross profit | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -13.4 | 0.0 |
| Gross margin | -382.2% | | | | | | -100.0% | |
| Selling, general and administrative | 8.6 | 8.6 | 7.2 | | | | | |
| Research and development | 12.8 | 18.2 | 16.8 | 14.3 | 19.2 | 15.8 | | 6.8 |
| General and administrative | | | | 7.6 | 8.7 | 8.0 | 7.7 | 3.3 |
| EBIT | -21.3 | -26.8 | -24.0 | -22.0 | -27.9 | -23.9 | -21.1 | -10.1 |
| EBIT margin | -47397.8% | | | | | | -157.4% | |
| Pre-tax income | 7.1 | -54.1 | -82.6 | -51.0 | -27.9 | -23.8 | -20.9 | -23.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 7.1 | -54.1 | -82.6 | -51.0 | -27.9 | -23.8 | 0.0 | -30.7 |
| Net margin | 15853.3% | | | | | | -0.2% | |
| |
| Diluted EPS | $0.13 | ($1.28) | ($2.38) | ($1.53) | ($0.84) | ($0.72) | ($0.64) | ($7.72) |
| Shares outstanding (diluted) | 53.3 | 42.1 | 34.7 | 33.4 | 33.1 | 33.1 | 0.0 | 4.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|